# Avammune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avammune-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.avammune.com
- Total disclosed funding: $12M
- Latest round: Series A (May 7, 2025)
- Investors on record: 5

## About

Based in the US, Avammune Therapeutics Inc. specializes in developing small molecule drug candidates that modulate the innate immune system, primarily targeting oncology applications.Founded in 2019 and headquartered in Philadelphia, US, Avammune Therapeutics Inc. focuses on creating innovative cancer therapies. The company has secured a total of USD 12.00 mn through 3 funding deals, with the latest being a Series A round on May 7, 2025, co-led by investors such as Capital 2B and Kotak Alternate Asset Managers. The founders, Aditya Kulkarni and Arun Papaiah, have experience in drug development and entrepreneurship.Avammune Therapeutics specializes in the discovery and development of small molecule drug candidates that modulate the innate immune system, with a strong focus on oncology applications. The company's core products include AVA-NP-695, an orally available ENPP1 inhibitor demonstrating significant antitumor potency and potential to reduce tumor metastasis, and AVA-ADR-001, a first-in-class small molecule inhibitor of ADAR1 showing promising anti-tumor efficacy in preclinical models. These products aim to address unmet medical needs in cancer treatment by enhancing immune responses and improving patient outcomes with solid tumors. The company primarily serves research institutions and pharmaceutical companies in North America, Europe, and Asia, where innovative cancer therapies are in high demand.Avammune Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies involved in drug development. Revenue is derived from licensing agreements for AVA-NP-695 and AVA-ADR-001, which are positioned as key assets for clinical trials and commercialization. Transactions typically include milestone payments tied to the advancement of drug candidates through various development stages, as well as royalties on future sales once the products are on the market. The company aims to leverage its proprietary pipeline to secure funding and strategic alliances, enhancing its financial sustainability while focusing on delivering effective cancer therapies.In May 2025, Avammune Therapeutics Inc. raised USD 12.00 mn in Series A funding to advance its proprietary immune pathway platform through preclinical development. The company plans to expand its pipeline of oral small molecule therapies and clinically develop its lead drug candidate. Recent funding will be utilized to support these initiatives and facilitate expansion into new markets, particularly targeting additional regions in North America and Asia by 2026.

## Funding rounds

- Series A, May 7, 2025, $12M — Kotak Alternate Asset Managers, IvyCap Ventures Group, 1Crowd, Shastra VC, Capital 2B

## Investors

- Kotak Alternate Asset Managers (https://capitalatlas.ai/funds/kotak-alternate-asset-managers) — Series A
- IvyCap Ventures Group (https://capitalatlas.ai/funds/ivycap-ventures-group) — Series A
- 1Crowd (https://capitalatlas.ai/funds/1crowd) — Series A
- Shastra VC (https://capitalatlas.ai/funds/shastra-vc) — Series A
- Capital 2B (https://capitalatlas.ai/funds/capital-2b) — Series A